Courtesy of The Journal Record
OKLAHOMA CITY – Monroe Capital said it acted as sole lead arranger and administrative agent on the funding of a $20 million senior credit facility for Cytovance Biologics Inc., by private equity sponsor, Great Point Partners.
Based in Oklahoma City, Cytovance is a contract manufacturing organization of mammalian and microbial biologics. The company works with biotechnology and pharmaceutical companies in the development and manufacturing of proteins, antibodies, and cell-based therapeutic products.
Chicago-based Monroe Capital is a provider of senior and junior debt and equity co-investments to middle-market companies.